Vivos Therapeutics Net Income 2011-2025 | VVOS

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Vivos Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-11.1 M	-13.6 M	-23.8 M	-20.3 M	-12.1 M	-10.8 M	-8.44 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-8.44 M	-23.8 M	-14.3 M

Quarterly Net Income Vivos Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-5.4 M	-5.01 M	-3.86 M	-	-2.62 M	-1.93 M	-3.76 M	-	-2.09 M	-5.53 M	-1.7 M	-	-5.43 M	-6.99 M	-5.33 M	-	-5.45 M	-4.04 M	-3.4 M	-	-1.81 M	-1.41 M	-2.58 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-1.41 M	-6.99 M	-3.8 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Medical devices industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
GenMark Diagnostics, Inc. GNMK	-18.6 M	-	-	$ 1.77 B	USA
Abiomed ABMD	226 M	-	-	$ 17.2 B	USA
Acutus Medical AFIB	-81.7 M	-	-26.83 %	$ 2.62 M	USA
Apyx Medical Corporation APYX	-18.7 M	$ 3.86	-3.26 %	$ 134 M	USA
Obalon Therapeutics, Inc. OBLN	-12.3 M	-	-5.86 %	$ 30.6 M	USA
Bio-Rad Laboratories BIO	-716 M	$ 307.92	-1.93 %	$ 8.69 B	USA
Apollo Endosurgery APEN	-39.8 M	-	-	$ 475 M	USA
BioSig Technologies BSGM	-10.3 M	-	37.08 %	$ 85.7 M	USA
Bruker Corporation BRKR	113 M	$ 45.13	-2.67 %	$ 6.72 K	USA
Allied Healthcare Products AHPI	-1.94 M	-	3.58 %	$ 2.21 M	USA
Abbott Laboratories ABT	13.4 B	$ 125.1	1.48 %	$ 218 B	USA
Boston Scientific Corporation BSX	1.85 B	$ 92.34	0.64 %	$ 136 B	USA
Conformis CFMS	-50.5 M	-	-	$ 16.4 M	USA
CryoLife, Inc. CRY	-16.7 M	-	-4.14 %	$ 702 M	USA
EDAP TMS S.A. EDAP	-19 M	$ 2.56	8.94 %	$ 95.5 M	France
Cardiovascular Systems CSII	-36.9 M	-	0.15 %	$ 844 M	USA
Cutera CUTR	-57.2 M	-	-10.19 %	$ 1.99 M	USA
OrthoPediatrics Corp. KIDS	-37.8 M	$ 17.7	-3.46 %	$ 408 M	USA
Soliton, Inc. SOLY	-14.5 M	-	-1.42 %	$ 435 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	-9.14 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	-10.9 M	-	0.03 %	$ 1.58 B	Israel
Misonix, Inc. MSON	-17.4 M	-	-	$ 462 M	USA
Neovasc NVCN	-24.9 M	-	-	$ 111 M	Canada
Eargo EAR	-157 M	-	-	$ 10.2 M	USA
Dynatronics Corporation DYNT	-10.9 M	-	14.99 %	$ 929 K	USA
Intersect ENT, Inc. XENT	-72.3 M	-	-	$ 955 M	USA
Xtant Medical Holdings XTNT	-16.4 M	$ 0.73	4.33 %	$ 97.6 M	USA
InMode Ltd. INMD	181 M	$ 14.56	0.76 %	$ 1.15 B	Israel
Cognyte Software Ltd. CGNT	-12.1 M	$ 9.88	0.05 %	$ 709 M	Israel
Second Sight Medical Products EYES	-23.5 M	-	-0.97 %	$ 54.4 M	USA
Align Technology ALGN	421 M	$ 165.15	0.78 %	$ 12.4 B	USA
Accuray Incorporated ARAY	-1.59 M	$ 1.07	-3.18 %	$ 110 M	USA
Avinger AVGR	-18.3 M	-	-20.74 %	$ 369 K	USA
ClearPoint Neuro CLPT	-18.9 M	$ 12.81	-1.23 %	$ 346 M	USA
FONAR Corporation FONR	12.4 M	$ 14.86	-0.03 %	$ 97.4 M	USA
AxoGen AXGN	-9.96 M	$ 30.33	1.15 %	$ 1.34 B	USA
Axonics Modulation Technologies AXNX	-59.7 M	-	-	$ 3.31 B	USA
GBS GBS	-10.6 M	-	-0.57 %	$ 7.12 M	USA
CONMED Corporation CNMD	132 M	$ 40.78	2.33 %	$ 1.26 B	USA
Globus Medical GMED	103 M	$ 86.83	-2.31 %	$ 11.8 B	USA
Integra LifeSciences Holdings Corporation IART	-6.94 M	$ 13.41	-4.56 %	$ 1.03 B	USA
Aziyo Biologics AZYO	-37.7 M	-	1.37 %	$ 20.5 M	USA
Alphatec Holdings ATEC	-162 M	$ 20.04	0.65 %	$ 2.86 B	USA
Aethlon Medical AEMD	-13.4 M	$ 3.4	-	$ 5.31 M	USA
Establishment Labs Holdings ESTA	-84.6 M	$ 72.58	-0.19 %	$ 2.04 B	Costa-rica
IRIDEX Corporation IRIX	-9.57 M	$ 0.92	-4.72 %	$ 14.8 M	USA
Electromed ELMD	7.54 M	$ 29.74	0.64 %	$ 251 M	USA
IRadimed Corporation IRMD	19.2 M	$ 96.35	-1.06 %	$ 1.22 B	USA